UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

The Lancet (British edition), 2020-10, Vol.396 (10257), p.1090-1100

2020

Volltextzugriff (PDF)

BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?

The lancet oncology, 2020-10, Vol.21 (10), p.1254-1255

Telli, Melinda L

2020

Volltextzugriff (PDF)

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Clinical cancer research, 2016-08, Vol.22 (15), p.3764-3773

2016

Volltextzugriff (PDF)

Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines

PloS one, 2012-05, Vol.7 (5), p.e33788-e33788

2012

Volltextzugriff (PDF)

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Journal of clinical oncology, 2018-08, Vol.36 (23), p.2433-2443

2018

Volltextzugriff (PDF)

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer

Proceedings of the National Academy of Sciences - PNAS, 2017-12, Vol.114 (52), p.13792-13797

2017

Volltextzugriff (PDF)

Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer

Circulation (New York, N.Y.), 2019-05, Vol.139 (21), p.2451-2465

2019

Volltextzugriff (PDF)

Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity

Nature medicine, 2016-05, Vol.22 (5), p.547-556

2016

Volltextzugriff (PDF)

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline

Journal of clinical oncology, 2016-07, Vol.34 (20), p.2416-2427

2016

Volltextzugriff (PDF)

Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility

Journal of clinical oncology, 2007-08, Vol.25 (23), p.3525-3533

2007

Volltextzugriff (PDF)

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

JAMA oncology, 2019-08, Vol.5 (8), p.1132

2019

Volltextzugriff (PDF)

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

Clinical cancer research, 2019-05, Vol.25 (9), p.2717-2724

2019

Volltextzugriff (PDF)

Induced Pluripotent Stem Cell-Based Cancer Vaccines

Frontiers in immunology, 2019-07, Vol.10, p.1510-1510

2019

Volltextzugriff (PDF)

Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow

BMC cancer, 2014-06, Vol.14 (1), p.456-456, Article 456

2014

Volltextzugriff (PDF)

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer

Clinical cancer research, 2018-06, Vol.24 (12), p.2851-2858

2018

Volltextzugriff (PDF)

Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer

Nature communications, 2023-04, Vol.14 (1), p.2053-2053, Article 2053

2023

Volltextzugriff (PDF)

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update

Journal of clinical oncology, 2021-02, Vol.39 (6), p.685-693

2021

Volltextzugriff (PDF)

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

Journal of clinical oncology, 2015-06, Vol.33 (17), p.1895-1901

2015

Volltextzugriff (PDF)

Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer

Annals of surgical oncology, 2016-10, Vol.23 (10), p.3310-3316

2016

Volltextzugriff (PDF)

Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer

Journal of clinical oncology, 2013-10, Vol.31 (29), p.3613-3615

Telli, Melinda L

2013

Volltextzugriff (PDF)

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer

Breast cancer research and treatment, 2018-04, Vol.168 (3), p.625-630

2018

Volltextzugriff (PDF)

Generation and characterization of induced pluripotent stem cells from breast cancer patients carrying ATM mutations

Stem cell research, 2023-12, Vol.73, p.103246-103246, Article 103246

2023

Volltextzugriff (PDF)

Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer

JCO oncology practice, 2020-01, Vol.16 (1), p.e37-e55

2020

Volltextzugriff (PDF)

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Clinical cancer research, 2022-04, Vol.28 (8), p.1540-1548

2022

Volltextzugriff (PDF)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

The oncologist (Dayton, Ohio), 2023-10, Vol.28 (10), p.845-855

2023

Volltextzugriff (PDF)

1 – 25 von 171

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(167)
Mit Volltextzugriff
(129)

Publikationsform

Artikel
(170)
Buchkapitel
(1)

Sprache

Englisch
(171)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

Science & Technology
(80)
Life Sciences & Biomedicine
(77)
Oncology
(67)
Humans
(64)
Female
(55)
Breast Cancer
(30)
Middle Aged
(20)
Tumors
(20)
Breast Neoplasms - Drug Therapy
(18)
Mutation
(17)
Adult
(16)
Chemotherapy
(15)
Breast Neoplasms - Genetics
(13)
Breast Neoplasms - Pathology
(13)
Triple Negative Breast Neoplasms - Drug Therapy
(13)
Triple Negative Breast Neoplasms - Genetics
(12)
Aged
(11)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Cancer
(11)
Medicine
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(10)

Menü

Weitere Dienste

Einstellungen

Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial

BROCADE3: a challenge to the treatment paradigm in BRCA breast cancer?

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update

Interferon-beta represses cancer stem cell properties in triple-negative breast cancer

Human-Induced Pluripotent Stem Cell Model of Trastuzumab-Induced Cardiac Dysfunction in Patients With Breast Cancer

Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline

Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility

Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

Induced Pluripotent Stem Cell-Based Cancer Vaccines

Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer

Antimicrobial exposure is associated with decreased survival in triple-negative breast cancer

Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Guideline Update

Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105

Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer

Insight or confusion: survival after response-guided neoadjuvant chemotherapy in breast cancer

Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer

Generation and characterization of induced pluripotent stem cells from breast cancer patients carrying ATM mutations

Decision Making About Genetic Testing Among Women With a Personal and Family History of Breast Cancer

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

Suchergebnisse filtern